Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
Bruce Strober, Andrew Blauvelt, Richard B. Warren, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 8, pp. 1543-1554
Open Access | Times Cited: 21

Showing 21 citing articles:

JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Application of deuterium in research and development of drugs
Jiong Chen, Yuan‐Yuan Zhu, Lu Huang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117371-117371
Closed Access | Times Cited: 1
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Real-world safety of deucravacitinib: insights from the Food and Drug Administration Adverse Event Reporting System
Kaidi Zhao, Shengxiang Xiao, Yang Zhao, et al.
International Journal of Clinical Pharmacy (2025)
Closed Access | Times Cited: 1
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
JAMA Dermatology (2024)
Open Access | Times Cited: 6
Dual‐Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self‐Locking Microneedles
Ziyi Wang, Ze Qiang Zhao, Yu Sheng, et al.
Advanced Science (2024)
Open Access | Times Cited: 4
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Joseph F. Merola, Laura K. Ferris, Jeffrey M. Sobell, et al.
Dermatology and Therapy (2025)
Open Access
Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2025)
Open Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review
Chul Hwan Bang, Chul Jong Park, Yoon‐Seob Kim
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1745-1745
Open Access
Exploring the Efficacy, Safety, and Clinical Implications of Deucravacitinib in East Asians with Psoriasis: A Narrative Review
Chul Hwan Bang, Chul Jong Park, Yoon‐Seob Kim
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1746-1746
Open Access
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
April W. Armstrong, Leon Kircik, Linda Stein Gold, et al.
Dermatology and Therapy (2025)
Open Access
Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database
Haowen Tan, Xiubi Chen, Xuan Ou, et al.
Research Square (Research Square) (2025)
Closed Access
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO‐4 Trial
Yukari Okubo, Akimichi Morita, Shinichi Imafuku, et al.
The Journal of Dermatology (2025)
Open Access
Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Y. Xu, X LIU, Linghong Guo, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 1121-1135
Open Access
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3778-3791
Closed Access | Times Cited: 2
Rosacea Fulminans following Initiation of Deucravacitinib
Meryl Thomas, Madhukar Paranjape, Rodney Sinclair
Clinical and Experimental Dermatology (2024)
Closed Access | Times Cited: 1
Tyrosine Kinase 2 Inhibitors: Synthesis and Applications in the Treatment of Autoimmune Diseases
Pan Lin, Juan Xu, Hongming Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117114-117114
Closed Access | Times Cited: 1
Pityriasis rosea-like drug eruption secondary to deucravacitinib
Nisal Punchihewa, Senhong Lee, Chin‐Guan Tan, et al.
JAAD Case Reports (2024) Vol. 53, pp. 63-65
Open Access
New Drug: Deucravacitinib for plaque psoriasis

Australian Prescriber (2024) Vol. 47, Iss. 6, pp. 195-196
Closed Access
Research progress on the pathogenesis of psoriasis and its small molecule inhibitors
Lulu Xia, Hongxin Li, Long Li, et al.
Archiv der Pharmazie (2024) Vol. 358, Iss. 1
Closed Access
Page 1

Scroll to top